Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.044115 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Hongbin Zang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Shengjing Hospital of China Medical University Shenyang China. Hauptthemen laut MEDLINE: Atrial Function, Left, Heart Atria, Heart Ventricles, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
It is unclear whether patients with heart failure with preserved ejection fraction respond to spironolactone based on cardiac structure or function.
Methods
A post hoc analysis was performed among participants with left ventricular (LV) ejection fraction ≥50% and evidence of abnormal LV diastolic function or filling pressures in TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial). Log‐rank tests and Cox regression models were used for comparison between groups.
Results
Totally, 757 subjects were qualified and stratified by parameters on cardiac structure or function. In patients with increased left atrial volume index, spironolactone reduced cardiovascular mortality (adjusted hazard ratio [HR], 0.48 [95% CI, 0.24–0.98]; P =0.042, log‐rank; interaction P =0.045). Meanwhile, in patients with increased LV mass index, spironolactone decreased heart failure hospitalization (adjusted HR, 0.51 [95% CI, 0.32–0.80]; P =0.009, log‐rank; interaction P =0.041) and the composite outcome of cardiovascular mortality, heart failure hospitalization, and aborted sudden death (adjusted HR, 0.63 [95% CI, 0.43–0.93]; P =0.045, log‐rank; interaction P =0.029). Then, in participants with increased left atrial volume index and LV mass index, who matched at 1:1 ration by propensity score matching, spironolactone reduced cardiovascular mortality (adjusted HR, 0.31 [95% CI, 0.11–0.92]; P =0.039, log‐rank), heart failure hospitalization (adjusted HR, 0.26 [95% CI, 0.10–0.68]; P =0.005, log‐rank), and the composite outcome (adjusted HR, 0.33 [95% CI, 0.15–0.72]; P =0.006, log‐rank).
Conclusions
Spironolactone reduced cardiovascular mortality, heart failure hospitalization, or the composite outcome of cardiovascular mortality, heart failure hospitalization, and aborted sudden death in patients with heart failure with preserved ejection fraction with increased left atrial volume index or LV mass index.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology Shengjing Hospital of China Medical University Shenyang China.
- Department of Neurology Shengjing Hospital of China Medical University Shenyang China.
ORCID-Profile: Hongbin Zang, Yilong Pan, Qiongyu Zhang
Zitieren
APA
Zang, H., Jia, C., Pan, Y., Li, X., & Zhang, Q. (2026). Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.044115
Vancouver
Zang H, Jia C, Pan Y, Li X, Zhang Q. Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.044115
BibTeX
@article{Zang2026,
author = {Zang, Hongbin and Jia, Chenhong and Pan, Yilong and Li, Xiaodong and Zhang, Qiongyu},
title = {Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.044115}
}
EUVIMED